Is HSIC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Mix shift toward specialty and technology, with revenue (ttm) at ~$13.60B. The bear case rests on distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Analysts covering it are spread from $64.00 to $112.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $64.00, -28.7% from the $89.77 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Mix shift toward specialty and technology. Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. The most optimistic analyst target on HSIC is $112.00, +24.8% from the $89.77 price. That figure is only reachable if this thesis works close to its best case.

Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Dental consumables and equipment demand depends on discretionary patient visits, and the softness that started in 2023 has not fully cleared. Tariffs and freight on imported dental and medical goods are a live cost input that cannot always be passed through quickly. The company has grown specialty and technology largely by acquisition, which carries integration risk and a large goodwill balance relative to equity. Manufacturers selling directly to practices, and pure-play e-commerce suppliers, continue to chip at the intermediary's role, and the 2023 cyberattack is a reminder of how concentrated the operational risk in an ordering platform can be. The most pessimistic published target is $64.00, -28.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

The largest distributor of dental and medical supplies to office-based practices, plus specialty implants and Dentrix practice software.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Mix shift toward specialty and technology) stalling in the reported numbers rather than in the narrative, the risk above (distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It is a distributor. Henry Schein buys dental and medical products from thousands of manufacturers and resells them to office-based dentists and physicians, roughly a million customers worldwide, alongside its own specialty product brands (implants, orthodontics, biomaterials) and practice-management software such as Dentrix.

HSIC trades on the NasdaqGS, so any US brokerage that offers listed equities can hold it. It also sits inside broad health care and mid-cap indexes, so many investors already own a small slice through funds. In Walnut you can add HSIC to a basket alongside other health care distribution or dental names and give the group a stated thesis and target weights.

Predominantly dental. Dental is the larger and more profitable side of the business and drives most of the sentiment on the stock, while medical distribution is a sizeable but low-margin second leg that activist investor Ananym has argued should be reviewed for divestiture.